Nateglinide: A glucose-sensitive insulinotropic agent that is chemically and pharmacologically distinct from the sulfonylureas

Current Opinion in Endocrinology and Diabetes

Volumn 6, Issue SUPPL. 1, 1999, Pages

  Dunning, Beth E ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIPIZIDE; MEGLITINIDE; NATEGLINIDE; POTASSIUM CHANNEL; REPAGLINIDE; TOLBUTAMIDE;

CHANNEL GATING; CONFERENCE PAPER; DRUG EFFECT; DRUG UPTAKE; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL;

EID: 0033460193     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Avignon A, Radauceanu A, Monnier L: Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997, 20:1822-1826.
2. Mitrakou A, Kelley D, Mokan M, et al.: Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992, 326:22-29.
3. nd edition. Oxford: Blackwell Science Ltd. 1997:pp 8.1-8.14.
4. Fujita T, Seto Y, Kondo N, et al.: Studies on the N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) receptor in HIT T-15 cells. Biochem Pharm 1996, 52:407-411.
5. Akiyoshi M, Kakei M, Nakazaki M, et al.: A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells. Am J Physiol 1995, 268:E185-E193.
6. Boettcher BR, Fanelli B, Geisse S, et al.: Receptor binding studies with A-4166 (Starlix*) [abstract 1015]. Diabetes 1998, 47(suppl 1):A261.
7. Leclercq-Meyer V, Ladriere L, Fuhlendorff J, et al.: Stimulation of insulin and somatostatin release by two meglitinide analogs. Endocrine 1997, 7:311-317.
8. Lebrun P, Malaisse WJ: Cationic and secretory effects of glimepiride and glibenclamide in perifused rat islets. Pharmacol Toxicol 1992, 70:357-360.
9. th International Diabetes Federation Symposium. Kobe, Japan; November 1994:418.
10. Dunning BE, de Souza C: The metabolic advantage of a rapid onset/short duration insulin secretagogue in the treatment of NIDDM [abstract]. Proceedings of the Keystone Symposium on Insulin Action and Secretion in NIDDM. Park City, Utah; January 1997:41.
11. de Souza CJ, Russo P, Lozito R, et al.: Comparative effects of A-4166, sulfonylureas and repaglinide on meal induced glucose excursions in normal rats [abstract]. Diabetologia 1997, 40(suppl 1):A45.
12. th International Diabetes Federation symposium. Kobe, Japan; November 1994:419.